Table 3. Oncological Outcomes.
| Outcome | Study groupa | P valueb | |
|---|---|---|---|
| Conventional hepatectomy (n = 41) | Anterior approach (n = 39) | ||
| Tumor cell detection | |||
| Preoperative bloodc | 12 (32) | 12 (32) | .57 |
| Preoperative bone marrowd | 9 (26) | 12 (32) | .80 |
| Intraoperative bloode | 5 (24) | 6 (27) | .54 |
| Follow-up | |||
| No evidence of disease | 8 (20) | 6 (15) | .47 |
| Alive with disease | 8 (20) | 4 (10) | |
| Death from disease | 15 (37) | 16 (41) | |
| Death from other reason | 1 (2) | 3 (8) | |
| Recurrence (first site) | 23 (56) | 17 (44) | |
| Liver | 10 (24) | 8 (21) | .46 |
| Adrenal gland | 2 (5) | 0 | |
| Lung | 9 (22) | 5 (13) | |
| Bone | 1 (2) | 2 (5) | |
| Nodal | 0 | 1 (3) | |
| Pelvic recurrence | 0 | 1 (3) | |
| Colon | 1 (2) | 0 | |
| Therapy of recurrence | |||
| Chemotherapy | 15 (37) | 10 (26) | .36 |
| Surgery | 2 (5) | 4 (10) | |
| Chemotherapy + surgery | 3 (7) | 2 (5) | |
| Loss to follow-up | 3 (7) | 1 (3) | |
a
Unless otherwise indicated, data are expressed as number (percentage) of patients. Percentages have been rounded and may not total 100.
b
The Wilcoxon rank sum test was performed for continuous parameters. Pearson χ2 test or Fisher exact test was performed for categorical parameters dependent on sample size.
c
Preoperative blood samples were available for 37 patients in the conventional and 38 in the anterior approach group.
d
Preoperative bone marrow samples were available for 34 patients in the conventional and 38 in the anterior approach group.
e
Intraoperative blood samples of 21 patients in the conventional and 22 in the anterior approach group were considered in this analysis.